Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Castle Biosciences, Inc.NASDAQ: CSTL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $14.43M rose 14.6% year over year, ahead of the +5.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Research & development amounted to 15.1% of revenue in FY2025, down 0.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +14.6% holds above the trailing-twelve-month pace of +5.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 51.85M USD
- Year-over-year change
- -0.4%
- 4-year CAGR
- +15.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.85M | -0.4% |
| FY2024 | 2024-12-31 | 52.04M | -2.9% |
| FY2023 | 2023-12-31 | 53.62M | +19.4% |
| FY2022 | 2022-12-31 | 44.9M | +51.5% |
| FY2021 | 2021-12-31 | 29.65M | — |
Research & Development vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's LTM Mar 2026 research & development of $53.69M is the 4th highest of the 8 companies compared; the peer median is $52.16M.
- Its year-over-year change of +5.8% is the 6th highest of 8, against a peer median of +7.6%.
- Research & development amounts to 15.8% of revenue for CSTL, versus a peer median of 12.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Jun 2026 | $93.37M | +31.8% | +20.4% | 16.6% | |
| LTM Mar 2026 | $53.69M | +5.8% | +4.9% | 15.8% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $12.42M | +19.5% | -2.9% | 12.9% | |
| FY2025 | $10.35M | -1.9% | +11.1% | 9.6% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $52.16M | +7.6% | +6.9% | 12.9% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 94.09M | 137.04M | 219.79M | 332.07M | 344.23M |
| Cost of Revenue | 15.82M | 32.01M | 44.98M | 60.21M | 71.03M |
| Gross Profit | 78.26M | 105.03M | 174.81M | 271.86M | 273.2M |
| Gross Margin | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Research & Development | 29.65M | 44.9M | 53.62M | 52.04M | 51.85M |
| Selling, General & Admin | 86.74M | 143M | 180.15M | 200.05M | 229.32M |
| Operating Expenses | 118.34M | 177.89M | 242.78M | 263.19M | 316.01M |
| Depreciation & Amortization | 3.41M | 10.54M | 12.33M | 16M | 40.77M |
| EBITDA | (36.6M) | (58.34M) | (45.02M) | 38.14M | 11.34M |
| EBITDA Margin | -38.9% | -42.6% | -20.5% | 11.5% | 3.3% |
| Operating Income | (40.08M) | (72.86M) | (67.98M) | 8.67M | (42.81M) |
| Operating Margin | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Interest Income | 68K | 3.97M | 10.62M | 12.92M | 11.77M |
| Interest Expense | 1K | 17K | 11K | 577K | 86K |
| Other Income / Expenses | 67K | 3.95M | 10.61M | 12.89M | 13.3M |
| Income Before Tax | (40.01M) | (68.9M) | (57.37M) | 21.56M | (29.51M) |
| Pre-Tax Margin | -42.5% | -50.3% | -26.1% | 6.5% | -8.6% |
| Income Tax Expense | (8.72M) | (1.77M) | 101K | 3.32M | (5.36M) |
| Net Income | (31.29M) | (67.14M) | (57.47M) | 18.25M | (24.16M) |
| Net Margin | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| EPS (Basic) | (1.24) | (2.58) | (2.14) | 0.66 | (0.83) |
| EPS (Diluted) | (1.24) | (2.58) | (2.14) | 0.62 | (0.83) |
| Weighted Avg Shares | 25.14M | 26.05M | 26.8M | 27.78M | 28.99M |
| Weighted Avg Shares (Diluted) | 25.14M | 26.05M | 26.8M | 29.26M | 28.99M |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.